Brave River Science Foundation aims to increase the number of Neurofibromatosis Type 1 (NF1) therapeutics that are brought to the clinic in the next 3-10 years. NF1 is a monogenic disorder affecting 100K patients in the US and 2M worldwide. Despite having 2 FDA-approved drugs, a significant unmet medical need remains. We are looking to partner with and fund biotechs that are interested in expanding into the NF1 indication.